

ORAL PRESENTATION

Open Access

# Medium-term results after implant of a new generation stentless aortic prosthesis: hemodynamic performance of medtronic 3F<sup>®</sup> stentless equine pericardial aortic valve

G Stefanelli\*, D Gabbieri, C Labia, G D'Anniballe, D Sarandria, R Santangelo, G Gioia

From 23rd World Congress of the World Society of Cardio-Thoracic Surgeons  
Split, Croatia. 12-15 September 2013

## Background

Aim of this study was to evaluate the clinical and hemodynamic results at 5 years of Medtronic 3F<sup>®</sup> stentless equine pericardial aortic valve.

## Methods

Between March 2007 and December 2012 a total of 120 consecutive patients affected by aortic valve disease received a 3F valve at our unit. The size ranged between 21 and 29, with prevalence of 23 and 25 implants. Mean age at operation was  $75,6 \pm 8,0$  years, 54% were males, the mean logistic EuroScore was  $8,7 \pm 5,2$  and 47% received concomitant procedures. For isolated replacements the mean ECC time was  $90' \pm 10'$ , Cross Clamp time  $72' \pm 8'$ . In 12 pts the aortic prosthesis was included in a Dacron tube straight graft for a Bentall operation.

## Results

Early mortality in isolated AVR was 2,1% and 3,1% in the entire group. There have been 6 late all-causes deaths (5,6%), with a survival of 90% at 5 yrs. 91% of patients are in NYHA class I or II. Actuarial freedom from reoperation for structural deterioration is 100% at 5 years. Freedom from endocarditis and thromboembolic events was 96% and 99% respectively. The 72 patients evaluated under exercise at 75w protocol showed a moderate increase in the MPG (from  $7,8 \pm 3,3$ mmHg to  $11,6 \pm 4,0$ mmHg) for the entire series at five years follow up.

## Conclusions

The 3F valve shows excellent hemodynamics, durability and freedom from structural deterioration at 5 yrs follow-up. Freedom from endocarditis and thromboembolic events looks satisfactory. Longer follow-up times are needed for a better evaluation of this interesting new generation of user friendly aortic valve substitute.

Published: 11 September 2013

doi:10.1186/1749-8090-8-S1-O320

Cite this article as: Stefanelli et al.: Medium-term results after implant of a new generation stentless aortic prosthesis: hemodynamic performance of medtronic 3F<sup>®</sup> stentless equine pericardial aortic valve. *Journal of Cardiothoracic Surgery* 2013 **8**(Suppl 1):O320.

### Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



\* Correspondence: [guglielmostefanelli@hotmail.com](mailto:guglielmostefanelli@hotmail.com)  
Cardiac Surgery, Hesperia Hospital, Modena, Italy